GDF15 and metabolic dysfunction-associated steatohepatitis: However, given that hepatic lipid accumulation and inflammation trigger fibrotic response in the progression of NASH, we cannot exclude the possibility that anti-fibrotic action of GDF15 is partly secondary to the reduced hepatic lipid accumulation and inflammation.